[go: up one dir, main page]

WO2008108323A1 - インフルエンザ治療剤 - Google Patents

インフルエンザ治療剤 Download PDF

Info

Publication number
WO2008108323A1
WO2008108323A1 PCT/JP2008/053738 JP2008053738W WO2008108323A1 WO 2008108323 A1 WO2008108323 A1 WO 2008108323A1 JP 2008053738 W JP2008053738 W JP 2008053738W WO 2008108323 A1 WO2008108323 A1 WO 2008108323A1
Authority
WO
WIPO (PCT)
Prior art keywords
influenza
drug
treatment
prevention
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/053738
Other languages
English (en)
French (fr)
Inventor
Makoto Yamashita
Yoshihiro Kawaoka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
University of Tokyo NUC
Original Assignee
Daiichi Sankyo Co Ltd
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002680415A priority Critical patent/CA2680415A1/en
Priority to US12/449,909 priority patent/US20100204314A1/en
Priority to PL08721158T priority patent/PL2123271T3/pl
Priority to DK08721158.7T priority patent/DK2123271T3/da
Priority to HK10103858.3A priority patent/HK1137142B/en
Priority to HR20110861T priority patent/HRP20110861T1/hr
Priority to AT08721158T priority patent/ATE526960T1/de
Priority to CN2008800149108A priority patent/CN101715343B/zh
Priority to EP08721158A priority patent/EP2123271B1/en
Priority to JP2009502568A priority patent/JP5286251B2/ja
Application filed by Daiichi Sankyo Co Ltd, University of Tokyo NUC filed Critical Daiichi Sankyo Co Ltd
Priority to SI200830440T priority patent/SI2123271T1/sl
Priority to ES08721158T priority patent/ES2372996T3/es
Publication of WO2008108323A1 publication Critical patent/WO2008108323A1/ja
Anticipated expiration legal-status Critical
Priority to US14/010,784 priority patent/US20140018418A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

　Ｈ５Ｎ１型インフルエンザの治療剤または予防剤を提供する。 　一般式（I）で表される化合物を有効成分として含有するＨ５Ｎ１型インフルエンザの治療剤または予防剤。 ［式中、Ｒ1、Ｒ2：Ｈ、アルカノイル；Ｘ：ハロゲン原子、ＯＨ、アルコキシ、アルカノイルオキシ；Ｒ3：Ｈ、アルキル。Ｒ1、Ｒ2：Ｈ；Ｘ：ＯＨ；Ｒ3：Ｈを除く。］
PCT/JP2008/053738 2007-03-07 2008-03-03 インフルエンザ治療剤 Ceased WO2008108323A1 (ja)

Priority Applications (13)

Application Number Priority Date Filing Date Title
EP08721158A EP2123271B1 (en) 2007-03-07 2008-03-03 Drug for treatment of influenza
PL08721158T PL2123271T3 (pl) 2007-03-07 2008-03-03 Lek do leczenia grypy
DK08721158.7T DK2123271T3 (da) 2007-03-07 2008-03-03 Lægemiddel til behandling af influenza
HK10103858.3A HK1137142B (en) 2007-03-07 2008-03-03 Drug for treatment of influenza
HR20110861T HRP20110861T1 (hr) 2007-03-07 2008-03-03 Lijek za liječenje gripe
AT08721158T ATE526960T1 (de) 2007-03-07 2008-03-03 Arzneimittel zur behandlung von grippe
CN2008800149108A CN101715343B (zh) 2007-03-07 2008-03-03 流感治疗药
CA002680415A CA2680415A1 (en) 2007-03-07 2008-03-03 Neuraminic acid derivatives useful in the treatment of influenza
US12/449,909 US20100204314A1 (en) 2007-03-07 2008-03-03 Drug for treatment of influenza
JP2009502568A JP5286251B2 (ja) 2007-03-07 2008-03-03 インフルエンザ治療剤
SI200830440T SI2123271T1 (sl) 2007-03-07 2008-03-03 Zdravilo za zdravljenje influence
ES08721158T ES2372996T3 (es) 2007-03-07 2008-03-03 Fármaco para el tratamiento de gripe.
US14/010,784 US20140018418A1 (en) 2007-03-07 2013-08-27 Methods of treating or preventing h5n1 influenza

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-056872 2007-03-07
JP2007056872 2007-03-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/010,784 Division US20140018418A1 (en) 2007-03-07 2013-08-27 Methods of treating or preventing h5n1 influenza

Publications (1)

Publication Number Publication Date
WO2008108323A1 true WO2008108323A1 (ja) 2008-09-12

Family

ID=39738201

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/053738 Ceased WO2008108323A1 (ja) 2007-03-07 2008-03-03 インフルエンザ治療剤

Country Status (16)

Country Link
US (2) US20100204314A1 (ja)
EP (1) EP2123271B1 (ja)
JP (2) JP5286251B2 (ja)
KR (1) KR101473028B1 (ja)
CN (1) CN101715343B (ja)
AT (1) ATE526960T1 (ja)
CA (1) CA2680415A1 (ja)
CY (1) CY1112201T1 (ja)
DK (1) DK2123271T3 (ja)
ES (1) ES2372996T3 (ja)
HR (1) HRP20110861T1 (ja)
PL (1) PL2123271T3 (ja)
PT (1) PT2123271E (ja)
SI (1) SI2123271T1 (ja)
TW (1) TWI424841B (ja)
WO (1) WO2008108323A1 (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
ES2442024T3 (es) 2008-07-15 2014-02-07 Academia Sinica Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
JP5947289B2 (ja) * 2010-05-10 2016-07-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗インフルエンザ活性を有するザナミビルホスホネート同族体およびインフルエンザウイルスのオセルタミビルに対する感受性の決定
CN104926802B (zh) * 2011-12-16 2018-02-13 第一三共株式会社 用于制备神经氨酸衍生物的方法
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
JP6302909B2 (ja) 2012-08-18 2018-03-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ シアリダーゼの同定および画像化のための細胞透過性プローブ
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
WO2015035337A1 (en) 2013-09-06 2015-03-12 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS
CA2937123A1 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
JP6562942B2 (ja) 2014-03-27 2019-08-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 反応性標識化合物およびその使用
AU2015267051B2 (en) 2014-05-27 2022-03-17 Academia Sinica Fucosidase from bacteroides and methods using the same
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20220151036A (ko) 2014-05-27 2022-11-11 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
IL249188B2 (en) 2014-05-27 2024-03-01 Academia Sinica Anti-her2 glycoantibodies and uses thereof
CN106714829A (zh) 2014-05-28 2017-05-24 中央研究院 抗TNF‑α醣抗体及其用途
CN107001404B (zh) 2014-09-08 2021-06-29 中央研究院 使用醣脂激活人类iNKT细胞
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
WO2016118191A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
CN109195996A (zh) 2016-03-08 2019-01-11 中央研究院 N-聚醣及其阵列的模组化合成方法
AU2017316663B2 (en) 2016-08-22 2024-02-22 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
US20210220378A1 (en) * 2017-10-11 2021-07-22 Lifescience As N-acetylneuraminic acid compositions and methods of use

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10109981A (ja) 1996-08-13 1998-04-28 Sankyo Co Ltd ノイラミン酸化合物
JPH10330373A (ja) * 1996-07-22 1998-12-15 Sankyo Co Ltd ノイラミン酸誘導体
JP2002012590A (ja) 2000-04-25 2002-01-15 Sankyo Co Ltd ノイラミン酸化合物の水和物及び結晶
US6340702B1 (en) 1996-07-22 2002-01-22 Sankyo Company, Limited Neuraminic acid derivatives, their preparation and their medical use
US6451766B1 (en) 1996-07-22 2002-09-17 Sankyo Company, Limited Neuraminic acid derivatives, their preparation and their medical use
US6844363B2 (en) 2000-04-25 2005-01-18 Sankyo Company, Limited Hydrates of a neuraminic acid compound and crystalline forms thereof
JP2007056872A (ja) 2005-08-22 2007-03-08 Delphi Technologies Inc カムシャフトとタイミングギアとの間のタイミングを制御するためのフェーザ

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0823428T3 (da) * 1996-07-22 2002-02-18 Sankyo Co Neuraminsyrederivater, deres fremstilling og deres medicinske anvendelse

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10330373A (ja) * 1996-07-22 1998-12-15 Sankyo Co Ltd ノイラミン酸誘導体
JP3209946B2 (ja) 1996-07-22 2001-09-17 三共株式会社 ノイラミン酸誘導体
US6340702B1 (en) 1996-07-22 2002-01-22 Sankyo Company, Limited Neuraminic acid derivatives, their preparation and their medical use
US6451766B1 (en) 1996-07-22 2002-09-17 Sankyo Company, Limited Neuraminic acid derivatives, their preparation and their medical use
JPH10109981A (ja) 1996-08-13 1998-04-28 Sankyo Co Ltd ノイラミン酸化合物
JP2002012590A (ja) 2000-04-25 2002-01-15 Sankyo Co Ltd ノイラミン酸化合物の水和物及び結晶
US6844363B2 (en) 2000-04-25 2005-01-18 Sankyo Company, Limited Hydrates of a neuraminic acid compound and crystalline forms thereof
JP2007056872A (ja) 2005-08-22 2007-03-08 Delphi Technologies Inc カムシャフトとタイミングギアとの間のタイミングを制御するためのフェーザ

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HIROKAWA SHOTEN: "Molecular Design", vol. 7, 1990, article "Development of Pharmaceuticals", pages: 163 - 198
LE Q MAI ET AL.: "Avian flu: isolation of drug- resistant H5N1 virus.", NATURE, vol. 437, no. 7062, 2005, pages 1108, XP008112478 *
MOSCONA ANNE: "Oseltamivir resistance -disabling our influenza defenses.", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 353, no. 25, 2005, pages 2633 - 2636, XP008112475, DOI: doi:10.1056/NEJMp058291 *
N. ENGL. J. MED., vol. 353, no. 25, 2005, pages 2667 - 72
NATURE, vol. 437, 2005, pages 1108
RUPERT J. RUSSE LL ET AL.: "The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.", NATURE, vol. 443, 2006, pages 45 - 49, XP002474738 *
See also references of EP2123271A4

Also Published As

Publication number Publication date
ATE526960T1 (de) 2011-10-15
US20140018418A1 (en) 2014-01-16
KR20090129414A (ko) 2009-12-16
EP2123271A1 (en) 2009-11-25
JPWO2008108323A1 (ja) 2010-06-17
PL2123271T3 (pl) 2012-03-30
HK1137142A1 (en) 2010-07-23
JP5286251B2 (ja) 2013-09-11
CN101715343A (zh) 2010-05-26
PT2123271E (pt) 2011-12-20
HRP20110861T1 (hr) 2011-12-31
TW200848018A (en) 2008-12-16
EP2123271B1 (en) 2011-10-05
JP2013139483A (ja) 2013-07-18
US20100204314A1 (en) 2010-08-12
CA2680415A1 (en) 2008-09-12
EP2123271A4 (en) 2010-03-17
SI2123271T1 (sl) 2012-05-31
DK2123271T3 (da) 2012-01-23
JP6012076B2 (ja) 2016-10-25
CN101715343B (zh) 2012-09-26
TWI424841B (zh) 2014-02-01
CY1112201T1 (el) 2015-12-09
ES2372996T3 (es) 2012-01-30
KR101473028B1 (ko) 2014-12-15

Similar Documents

Publication Publication Date Title
WO2008108323A1 (ja) インフルエンザ治療剤
TNSN08407A1 (en) Organic compounds
WO2009051670A3 (en) Oxylipin compounds for the treatment of ophthalmic conditions
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
WO2008083248A3 (en) Cyclopamine analogs
WO2008062905A3 (en) Heteromonocyclic compound and use thereof
MY158982A (en) Heterocyclic compound
MY148703A (en) Polycyclic cinnamide derivatives
WO2009051119A1 (ja) ピリミジルインドリン化合物
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2008099874A1 (ja) ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法
WO2010091197A3 (en) Tablets for combination therapy
HK1202288A1 (en) 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives
WO2008126901A1 (ja) 含窒素複素環化合物およびそれを含有する医薬組成物
WO2009051223A1 (ja) 白内障処置のための医薬組成物
WO2008153129A1 (ja) 尿酸値低下剤
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2009145591A3 (en) Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof
WO2008019030A3 (en) Modified azole compounds as antiinfective agents
WO2008136378A1 (ja) 新規なスルホンアミド誘導体またはその塩
MX2009004991A (es) Derivados de monoacetato de ciclopenteno-diol.
WO2009063897A1 (ja) 皮膚の乾癬予防または改善剤
WO2009018551A3 (en) Therapeutic compounds
WO2008141097A3 (en) Stereoisomers propofol therapeutic compounds
WO2008098143A3 (en) Antimicrobial compounds and methods of use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880014910.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08721158

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009502568

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020097018422

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2680415

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008721158

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12449909

Country of ref document: US